无容量
医学
血液透析
转移性黑色素瘤
内科学
黑色素瘤
疾病
胃肠病学
癌症
免疫疗法
癌症研究
作者
Judith L Gulikers,Sander Croes,Marco J W Schreurs,Elisabeth J R Litjens,Maureen J.B. Aarts,Robin M.J.M. van Geel
出处
期刊:Melanoma Research
[Ovid Technologies (Wolters Kluwer)]
日期:2021-09-13
卷期号:31 (6): 579-581
被引量:2
标识
DOI:10.1097/cmr.0000000000000775
摘要
The effect of intermittent hemodialysis (IHD) on nivolumab serum concentrations in patients with severe renal impairment is largely unknown. Here, we present a 79-year-old patient with metastatic melanoma and end-stage renal disease on IHD three times a week, treated with 480 mg nivolumab every 4 weeks. A serum trough concentration of nivolumab was determined before the start of the third cycle, and two samples were taken immediately before and after a hemodialysis session during this cycle. All nivolumab serum concentrations were within a similar range as those previously measured among patients without renal insufficiency, after a comparable duration of nivolumab treatment. Therefore, we conclude that IHD does not influence nivolumab exposure. Furthermore, nivolumab treatment was continued without complications and appears to be well tolerated for patients on IHD.
科研通智能强力驱动
Strongly Powered by AbleSci AI